These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11890186)

  • 1. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study.
    Fukuchi T; Kanemoto K
    Int Clin Psychopharmacol; 2002 Mar; 17(2):53-8. PubMed ID: 11890186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
    Leinonen E; Lepola U; Koponen H; Mehtonen OP; Rimon R
    Acta Psychiatr Scand; 1997 Dec; 96(6):497-504. PubMed ID: 9421348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G;
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamine.
    Ansseau M; von Frenckell R; Gérard MA; Mertens C; De Wilde J; Botte L; Devoitille JM; Evrard JL; De Nayer A; Darimont P
    Eur Neuropsychopharmacol; 1991 May; 1(2):113-21. PubMed ID: 1821700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical utility of milnacipran in comparison with other antidepressants.
    Bisserbe JC
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S43-50. PubMed ID: 12369610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.
    Claghorn JL; Earl CQ; Walczak DD; Stoner KA; Wong LF; Kanter D; Houser VP
    J Clin Psychopharmacol; 1996 Apr; 16(2):113-20. PubMed ID: 8690826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milnacipran. A review of its use in depression.
    Spencer CM; Wilde MI
    Drugs; 1998 Sep; 56(3):405-27. PubMed ID: 9777315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled comparison of milnacipran and fluoxetine in major depression.
    Ansseau M; Papart P; Troisfontaines B; Bartholomé F; Bataille M; Charles G; Schittecatte M; Darimont P; Devoitille JM; De Wilde J
    Psychopharmacology (Berl); 1994 Feb; 114(1):131-7. PubMed ID: 7846195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S; Arita S
    Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
    Grassi B; Gambini O; Scarone S
    Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods].
    Higuchi H
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):71-6. PubMed ID: 20491280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
    Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
    J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.
    Kasper S; Pletan Y; Solles A; Tournoux A
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():35-9. PubMed ID: 8923125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.